Analysis Of Clinical Features And Prognosis In Patients With Refractory/Relapsed Acute Myeloid Leukemia

ObjectiveTo investigate the potential prognosis factors for patients with refractory/relapsed acute myeloid leukemia (AML) through analyzing the clinical features of the patients admitted in our department.MethodsA retrospective research of 45 inpatients with refractory/relapsed AML was performed to assess the relationship between prognostic factors and overall survival (OS) from January 2007 to December 2015. The clinical features include gender, age, FAB classification of AML, performance status (PS), cytogenetic and molecular abnormities, complete remission (CR) duration, whether relapsed after hematopoietic stem cell transplantation (HSCT) and the therapy after relapse.ResultsThe mean survival time of the 45 patients with refractory/relapsed AML was (36.25 ±8.40) months and the median follow up was (9±2.58) months. The one-year and two-years overall survival rate was (40.6±7.5)% and (23.7±7.0)%. Univariate analysis results demonstrated that age≥60 years or failing to undergo HSCT after relapse had poor influence on OS.ConclusionThough the single center study, we may get the conclusion that performance of HSCT after relapse/refractory can improve the prognosis. HSCT is still the effective salvage therapy for patients with refractory/relapsed AML. Clinicians may be benefit from our research as it can help them choose the treatment for the patients with relapsed/refractory AML. It may result in the better survival for these patients.